Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria
Article information
Abstract
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline). In 2018, the World Health Organization revised the groupings of TB medicines and reclassified linezolid as a group A drug for the treatment of MDR-TB. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Although linezolid has a good efficacy, it can cause substantial adverse events, especially hematologic toxicity. In both TB infection and linezolid mechanism of action, mitochondrial dysfunction plays an important role. In this concise review, characteristics of linezolid as an anti-TB drug are summarized, including its efficacy, pathogenesis of hematologic toxicity highlighting mitochondrial dysfunction, and the monitoring and management of hematologic toxicity.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid, the two most effective anti-tuberculosis (TB) drugs. As a result, it requires treatment with a second-line regimen [1]. Extensively drug-resistant TB (XDR-TB) is a type of MDR-TB. It is caused by an organism that is resistant to quinolone and one of group A TB drugs (i.e., linezolid and bedaquiline) [2]. Currently, drug-resistant TB is a major public health burden. In 2020, the World Health Organization (WHO) reported that approximately 500,000 people worldwide had rifampicin-resistant tuberculosis (RR-TB), of which 78% developed MDR-TB. The global treatment success rate for MDR/RR-TB was 57% [3].
In 2018, the WHO revised the groupings of TB medicines and reclassified reclassified linezolid as a group A drug for the treatment of MDR-TB. Unless contraindicated, linezolid should be the first concern in the initial regimen for MDR/XDR-TB [4]. In 2020, the WHO Global TB Programme announced updated guidelines on the treatment of drug-resistant TB. Most MDR/XDR-TB patients can be treated with solely oral drug regimens without the use of injectable drugs [5]. Through collaboration, the American Thoracic Society, Centers for Disease Control and Prevention, the European Respiratory Society, and the Infectious Diseases Society of America released guidelines for the treatment of drug-resistant TB in November 2019. These guidelines have prioritized the use of an all-oral regimen. Linezolid is recommended in the regimen for MDR-TB [6]. However, the use of linezolid has a substantial risk of toxicity. Its optimal dose and duration remain undefined. On the other hand, linezolid is safe and well tolerated when it is used in short courses (<28 days) for infections other than TB [7]. In cases with a longer treatment, such as when its used for MDR/XDR-TB treatment (typically 6 months or longer), linezolid is associated with frequent serious, dose-dependent, and duration-dependent adverse effects, including anemia, neutropenia, thrombocytopenia, peripheral neuropathy, and more rarely, optic neuropathy, lactic acidosis, pancreatitis, and rhabdomyolysis [7]. A detrimental event (particularly hematological, neurological, and gastrointestinal) was experienced in 58.9% subjects, mostly in a cohort of individuals treated with an oral daily dosage >600 mg [8,9]. These adverse events can result in early cessation or reduction in the dose, which may compromise the efficacy of the drug.
Risks and predictor factors for hematological toxicities with linezolid remain unclear. The current focus is primarily on the efficacy and toxicity of a linezolid regimen in MDR-TB and XDR-TB. Comprehensive review of linezolid itself is limited, including pathogenesis, risk factors of hematologic toxicities, and on how to monitor and manage any problems that might occur. Linezolid inhibits mitochondrial ribosomes, which might be the cause of hematological alterations. However, little is known about the mechanisms involved in linezolidassociated mitochondrial toxicity in humans [10,11].
Because of the importance of linezolid in the treatment of MDR/XDR-TB and the high number of reports on its hematologic toxicities, the goal of this review is to increase awareness and understanding of hematologic toxicities of linezolid in MDR/XDR-TB with a focus on the role of mitochondria.
Data Sources
The databases searched were Medline via PubMed, Cochrane Database of Systematic Reviews via Ovid, and EmBase (January 2000 to July 2020). Searches were performed in July 2020. Data for this review were identified by searches of PubMed using “multidrug resistant tuberculosis,” “extensively resistant tuberculosis,” and “linezolid” as free text and MeSH terms in combination with other terms including “hematologic toxicity,” “bone marrow suppression,” or myelotoxicity (Figure 1).
Study selection.
Linezolid: Drug invention, Chemistry, Mode of Action, and Pharmacology
1. Drug invention
Linezolid was discovered in the mid-1990s. It was approved for commercial use in 2000 as an antibiotic for the treatment of all major Gram-positive bacterial pathogens of humans [12]. Linezolid is a synthetic antimicrobial agent in the oxazolidinone class. Since its approval in 2000, it has remained the primary drug in that class. It is used in therapy because of its distinctive mode of action, which involves inhibition of protein synthesis. As a synthetic antibiotic, linezolid can block the biosynthesis of bacterial proteins by binding to rRNA on both the 30S and 50S ribosomal subunits [13].
2. Chemistry
The empirical formula of linezolid is C16H20FN3O4 (molecular weight: 337.35 g/mol) (Figure 2). Studies on structure–activity relations of oxazolidinones have indicated that the N-aryl group and 5-S configuration are crucial for its activity [14]. The 5-acylaminomethyl group is all important for its activity. Its activity is high because of the electron-withdrawing group in the aryl ring. Extra-replacement on the proximal aromatic ring does not affect its antibacterial activity, although it can change its solubility and pharmacokinetics [14].
3. Pharmacokinetics
Oral absorbance of linezolid is remarkable, with 100% bioavailability. It is not influenced by food. An intravenous route can be changed to an oral one in clinically stable patients [14,15]. The plasma protein-binding level of this molecule is approximately 31%. The plasma half-life of linezolid is 3.4 hours to 7.4 hours [14]. Linezolid has volume distribution that approximates whole-body water content of 40–50 L. The compound is metabolized to inactive metabolites, including hydroxyethyl glycine and aminoethoxy-acetic acid. Linezolid has a clearance rate of 80±29 mL/min through both nonrenal and renal mechanisms. Renal tubular reabsorption may occur. An unaltered form of some fraction of its dose is excreted in urine [14,15].
After a five-fold increase in dose, a low level of nonlinearity was found, with a 30% decrease in clearance [14]. Elderly patients, those with mild to moderate hepatic damage or mild to moderate chronic renal failure, and healthy or young volunteers show no difference in plasma concentration [14]. A sevento eight-fold increase in exposure to drug metabolites has been reported in patients with severe renal impairment on dialysis than in patients with normal renal function [14]. Clearance of linezolid is higher in children than in adults. Therefore, higher daily doses of drug per kilogram of body weight are required in children than in adults [14].
4. Pharmacodynamics
Linezolid is an antimicrobial agent with a long duration and time-dependent activity. The value of the area under the curve/minimum inhibitory concentration (AUC/MIC) and the time that the plasma concentration is above the MIC (%T >MIC) are used as parameters to evaluate pharmacodynamics. Linezolid has a post antibiotic effect. The best pharmacokinetic/pharmacodynamics parameters to determine its activity are time with serum concentrations higher than the minimum inhibitory concentration (T > MIC) and the AUC/MIC ratio. Linezolid is primarily a bacteriostatic antimicrobial agent. T > MIC of at least 40% is predictive of its efficacy [15]. In healthy volunteers, this objective can be achieved for pathogens with MICs of 2–4 mg/L by administering 600 mg intravenously twice a day [15].
Efficacy of Linezolid Regimen for MDR-TB and XDR-TB
Most trials of linezolid effects on TB included subjects with MDR-TB and XDR-TB. Efficacy of linezolid in treatment of drug-resistant TB has been evaluated in several reviews. Zhang et al. [16] have conducted a systematic review and metaanalysis of 15 studies (367 patients). They found that 83% (95% confidence interval [CI], 75%–90%) of outcomes were favorable (either cure or treatment completion). The pooled rate of culture conversion was 89% (95% CI, 83%–95%). Of those 367 patients, 46.3% had XDR-TB. Cox and Ford [17] have reviewed 11 studies (148 patients). They found that the pooled proportion for treatment success was 67.9% (95% CI, 58.0%–78.9%). Of those subjects, 28% had XDR-TB. Agyeman and Ofori-Asenso [18] have conducted systematic review and meta-analysis of 23 studies in 14 countries involving 507 patients. The pooled proportion for treatment success was 77.4% (95% CI, 71.4%–82.8%), with a culture conversion rate of 88.4% (95% CI, 83.8%–92.4%). Lifan et al. [19] have conducted systematic review and meta-analysis of 72 original studies that included 302 patients with XDR-TB treated with linezolid. Pooled estimates for sputum culture conversion and treatment success rates were 93.2% and 67.4%, respectively.
Individual patient analysis has been reported in three meta-analyses. Sotgiu et al. [8] have reported individual data from 121 patients treated with linezolid. Pooled estimates of anti-TB treatment success and culture conversion were 82% and 93%, respectively. Median time to sputum smear and culture conversion were 43.5 days and 61 days, respectively. Chang et al. [20] have evaluated 194 patients from 20 articles. They found that linezolid increased the probability of favorable outcome by 55% (10% to 121%). Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017 [21] have evaluated 12,030 patients from 25 countries in 50 studies. The overall treatment success rate was 61% (n=7,346). However, 1,017 patients (8%) suffered failure or relapse and 1,729 patients (14%) died. Treatment success was positively associated with the use of linezolid (adjusted risk difference, 0.15; 95% CI, 0.11–0.18) compared with failure or relapse.
Two randomized studies have found improved treatment outcomes with linezolid in XDR-TB. Lee et al. [22] have evaluated 41 patients with XDR-TB. They found higher culture conversion at four months after randomization (relative risk [RR], 2.26; 95% CI, 1.19–4.28) when linezolid was given immediately than with a delay of two months. By four months, 15 of 19 patients (79%) in the immediate-start group and seven of 20 (35%) in the delayed-start group had culture conversion (p=0.001).
Tang et al. [23] have conducted a multicenter, prospective, randomized, controlled study of 65 subjects with XDR-TB. They found a significantly higher cure rate (RR, 2.36; 95% CI, 1.13–4.90) and a lower failure rate (RR, 0.26; 95% CI, 0.10–0.70) in subjects treated with linezolid than in those who were not. The proportion of sputum culture conversion in the linezolid therapy group was 78.8% by 24 months, significantly higher than that in the control group (37.6%, p<0.001). The treatment success rate in the linezolid therapy group was 69.7%, significantly higher than that in the control group (34.4%, p=0.004).
Mitochondria in TB and Linezolid Toxicity
1. Mitochondria in TB
Mitochondria have important roles in the cell death pathway and TB infection [24-26]. Mycobacterium tuberculosis (M.tb) targets mitochondria to increase replication by disturbing the cellular death pathway in alveolar macrophages [27]. M.tb secretes proteins that can cause changes in their structures (size, form, number, distribution, fragmentation) and functions of mitochondria. Inhibition of mitochondrial function can lead to increased growth of M.tb and persistent infection [28,29].
Necrosis and apoptosis are the two processes that can affect macrophages in TB infection. Infection with a virulent strain (H37Rv) of M.tb can cause damage to mitochondrial membranes in macrophages, increasing cytochrome c release from intermembrane spaces and causing further necrosis [29,30]. Necrosis of macrophages caused by M.tb is the mechanism involved in the further dissemination of the pathogen and disease development [26].
Infection with an attenuated M.tb strain (H37Ra) can cause apoptosis of macrophages, which can retain M.tb in apoptotic bodies to inhibit pathogen dissemination. Apoptosis of macrophages promotes antibacterial activity by increasing antigen presentation, allowing the innate immune system to reduce infection [26].
2. Mitochondria in linezolid toxicity
Linezolid inhibits bacterial protein synthesis and further interferes with the growth of bacteria by a mechanism that involves disturbance of bacterial mitochondria [10,31]. Mitochondria are important organelles that can initiate or amplify signals of apoptotic cell death [11,32]. Mitochondria originated as ancient proteobacteria engulfed by eukaryotic cells in order to obtain energy from utilization of oxygen. Therefore, there are evolutionary resemblances between mitochondrial and bacterial ribosomes. Interactions between ribosomal-inhibitor antibiotics such as linezolid and the host can have severe clinical effects common to primary mitochondriopathies [10,33-38].
Linezolid can bind to mitochondrial ribosomes, damage the expression and biosynthesis of mitochondrial proteins encoded by the mitochondrial genome, and block the action of cytochrome c-oxidase and mitochondrial oxidative activity [31,39]. The degree of exposure of a microorganism to this antibiotic as estimated by the AUC/MIC ratio is associated with the effectiveness of linezolid. Inhibition of mitochondrial ribosomes is also correlated with the level of linezolid exposure [40]. However, little is known about linezolid tissue specificity. Mitochondrial haplogroup U, mutations in 12S rRNA, and m.2706A → G, m.3197T → C, and m.3010G → A polymorphisms in 16S rRNA tend to be associated with increased mitochondrial and clinical adverse effects [32].
Hematologic Toxicity
1. Pathogenesis of hematologic toxicity
Suppression of bone marrow by linezolid is usually related to dose and duration of treatment, although it occurs infrequently during days 10–14 after drug administration [34]. Two possible mechanisms are considered to be responsible for thrombocytopenia side effects. One is bone marrow suppression of platelet production [41-43]. Linezolid can increase myosin light chain 2 phosphorylation, followed by repression of platelet release from mature megakaryocytes in an in vitro investigation using human megakaryoblast (MEG-01) [42]. The second mechanism is increased platelet destruction due to an immune mechanism [34,44].
Linezolid and its metabolites can bind to glycoprotein membrane IIb/IIIa to form IgG antibody complex by fragment antigen-binding. The fragment crystallizable portion can attach to macrophages. The reticuloendothelial system then destroys the platelet–linezolid–IgG complex [44].
An in vivo study with mice has shown that linezolid can affect precursor colony forming unit–erythroblasts, burst forming unit–erythroblasts, and erythroblasts in bone marrow [45]. Linezolid can repress the proliferation and cellular metabolite activity and interfere with mitochondrial function. Linezolid can also block mitochondrial protein biosynthesis and decrease ATP production in bone marrow precursor cells [45]. Mechanisms underlying linezolid-induced anemia are currently unclear. However, vacuolated pronormoblasts suggest the mechanism of anemia is identical to that of chloramphenicol-induced myelosuppression. Suppression of mitochondrial respiration via inhibition of mitochondrial protein synthesis is likely the mechanism. Pure red cell aplasia has also been reported as one mechanism of linezolid-induced anemia [35,46].
Figure 3 shows a schematic of linezolid-induced hematologic toxicities.
Schematic of linezolid-induced hematologic toxicities. Bacterial ribosomes are composed of two subunits: a large 50S subunit and a small 30S subunit. Linezolid binds to 23S rRNA in the large subunit of the prokaryotic ribosome, preventing bacterial protein synthesis and inhibiting bacterial growth. Mitochondrial ribosomes are generally similar to their bacterial counterparts. Linezolid interrelates with mitochondrial ribosomes, interferes with mitochondrial protein synthesis, and reduces ATP in bone marrow precursor cells in subjects at risk of drug accumulation and in those inherently more susceptible to mitochondrial toxicity. The mitochondrial dysfunction causes bone marrow suppression, leading to anemia, leukopenia, and thrombocytopenia.
Risk Factors for Hematologic Toxicity of Linezolid
Risk factors for hematologic toxicity are shown in Table 2.
Risk factors for hematologic toxicity of linezolid
Figure 4 provides a schematic summary of the role of mitochondria in TB and hematologic toxicity of linezolid.
A schematic summary of the role of mitochondria in tuberculosis (TB) and hematologic toxicity of linezolid. Mycobacterium tuberculosis can disrupt the mitochondrial permeability transition pore complex (mPTPC) and cause mitochondrial dysfunction. Linezolid can also cause mitochondrial dysfunction. These two mechanisms can inhibit mitochondrial protein biosynthesis, decrease ATP in bone marrow precursor cells, and cause myelosupression (anemia, neutropenia, and thrombocytopenia). Other mechanisms that can contribute to hematologic toxicities include disturbance in phosphorylation of myosin light chain 2 in megakaryocytes, which suppresses platelet release, and the complex of linezolid–platelet membrane glikoprotein IIb/IIIa–IgG. Dose, duration, platelet baseline, renal failure, liver dysfunction, albumin, cardiovascular disease, malignancy, caspofungin, levofloxacin, and carbapenem combination can also influence the development of hematologic toxicities. MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis.
Monitoring
When using linezolid, it is necessary to monitor blood counts (weekly during initial phase, then monthly) and signs and symptoms of peripheral neuropathy and retinitis. Monitoring varies considerably among studies. Natsumoto et al. [59] measured platelet counts two to three times per week. Hanai et al. [58] assessed hematological and biochemical parameters after four days of linezolid treatment. Conradie et al. [52] evaluated side effects of treatment weekly to week 16, at weeks 20 and 26, and then at one, two, and three months after the end of treatment and every three months thereafter to 24 months after the end of treatment.
In 2016, the Curry International Tuberculosis Center recommended complete blood counts monthly for patients on linezolid [60]. The United States Agency for International Development Tuberculosis CARE recommends a complete blood count check before starting linezolid, weekly during the first month, and then monthly, with additional checks if there are any symptoms or signs of myelosuppression [61].
The World Health Organization recommends monitoring for linezolid treatment, with hemoglobin and white blood cell count monitored weekly at first and then monthly or as needed based on symptoms. Any adverse events throughout treatment should be managed immediately to relieve suffering, minimize the risk of treatment interruptions, and prevent morbidity and mortality [5].
Clinical Management of Myelosuppression According to Severity Grading
The clinician should make reasonable judgments whether to continue, reduce, or stop linezolid if myelosuppression occurs. The risks and benefits of continuing linezolid should be considered carefully in this situation. The EndTB Consortium recommends clinical management of myelosuppression according to severity grading (Table 3) [62].
There are no firm guidelines on how to re-administer linezolid after stopping the drug. However, several previous studies have recommended how to re-administer linezolid.
A Nix-TB study used linezolid at 1,200 mg per day as the initial dose [52]. According to the protocol, dose reduction to 600 mg daily and 300 mg daily or temporary cessation of linezolid is permitted.
Cattaneo et al. [63] have recommended therapeutic drug monitoring (TDM) of linezolid to maintain an AUC/MIC ratio of 100 and adjust the linezolid dose. The linezolid dose has been reduced to less than 300 mg/day without compromising efficacy. A dose reduction to 200 or even 150 mg of linezolid once daily can be considered when the AUC/MIC ratio is sufficiently high. For patients who develop dose-dependent toxicity, TDM should be considered to reduce linezolid doses on re-administration [64,65].
Conclusion
Linezolid is a promising option for treating MDR-TB and XDR-TB. However, hematologic toxicity is the major concern with a linezolid-containing regimen. Several clinical factors are considered as risk factors for its hematologic toxicity. Linezolid can block mitochondrial protein biosynthesis, reduce ATP production in bone marrow precursor cells, and cause myelosuppression. Increased sensitivity to linezolid in mitochondrial ribosomes might be associated with genetic variation in human mitochondria. Further studies are needed to address how to identify patients who will develop myelosuppression. Such studies should begin by identifying potential biomarkers of mitochondrial dysfunction and genetic susceptibility to predict myelosuppression. In the future, it will be necessary to evaluate whether adjusting the concentration of linezolid in the serum to obtain the pharmacodynamic target is a reasonable strategy to avoid adverse events in patients receiving prolonged courses of linezolid.
Notes
Authors’ Contributions
Conceptualization: Oehadian A, Santoso P, Menzies D, Ruslami R. Writing - original draft preparation: Oehadian A, Santoso P. Writing - review and editing: Menzies D, Ruslami R. Approval of final manuscript: all authors.
Conflicts of Interest
No potential conflict of interest relevant to this article was reported.
Funding
This research and article processing charge (APC) were funded by the Doctoral Disertation Research Program with an internal Universitas Padjadjaran research funding number of 1595/UN6.3.1/PT.00/2021 and ALG (Academic Leadership Program) and internal Universitas Padjadjaran research funding number of 3855/UN.C/LT/2019.
Acknowledgements
The authors thank Kevin Y. Budiman, MD, for final editing and submitting the manuscript.